ZolpidemPrincipal Investigator: John Whyte, MD, PhD
Trial location: MossRehab

This trial seeks to define more precisely the proportion of patients in the vegetative and minimally conscious states (VS/MCS) who have a clinically meaningful response to zolpidem with improvement in their level of consciousness. It will use cutting-edge research methods (functional neuroimaging, event related potentials, etc.) to identify differences in brain anatomy and physiology between those who can and cannot respond to the drug. The investigators will also research registry of individuals in VS/MCS who may wish to participate in future research on this topic. For inclusion criteria and enrollment information, call 215-663-6456 or email participants@einstein.edu.

Amantadine

Principal Investigator: Joseph Giacino, PhD (JFK Johnson Rehabilitation Institute)
Co-Principal Investigator: John Whyte, MD, PhD
Trial location: Multicenter

This multicenter trial will determine whether amantadine is effective in improving functional recovery from the VS/MCS, as well as if any treatment advantage that is found is transient or remains after the drug is withdrawn. It will also compare the response to amantadine of those who are VS vs. MCS when treated, or earlier or later after injury when treated. For inclusion criteria and enrollment information, contact Mary Czerniak at meczerni@einstein.edu.

ReWalk

Principal Investigator: Alberto Esquenazi, MD
Trial location: MossRehab

The ReWalk is a motorized exoskeleton suit that enables patients with lower limb disabilities, including complete paralysis, to independently engage in ambulatory activities, such as standing, walking and in some cases climbing stairs. The trial will be a single-center, open, noncomparative, non-randomized study of the safety and performance of the ReWalk. The overall objectives and endpoints of this clinical trial are to establish the safety and performance of the ReWalk suit and demonstrate initial efficacy and user satisfaction. For inclusion criteria and enrollment information, contact Thomas Coulter at CoulterT@einstein.edu.

LokomatPrincipal Investigator: Alberto Esquenazi, MD
Trial location: MossRehab

This is a prospective, randomized study that will collect self-selected and maximal gait speed measured overground by Gait Mat for two groups: robotic-assisted Lokomat; and partial body weight supported treadmill training among patients with traumatic brain injury. The purpose of this pilot study is to collect self-selected and maximal possible gait speed data before and after robotic-assisted Lokomat training or partial body weight supported treadmill training that will allow calculation of statistical power and necessary sample size for a definitive future multicenter clinical trial in a traumatic brain injury population with gait dysfunction. For inclusion criteria and enrollment information, contact Stella Kim at kimst@einstein.edu.